Schizophrenia – Market Access and Reimbursement Insights Report – 2025
Schizophrenia Market Access and Reimbursement Insights
Thelansis’s “Schizophrenia
Market Access and Reimbursement Insights Report – 2025″ provides
comprehensive payer insights on the current and evolving market access and
reimbursement environments for branded and emerging drugs in the indication.
Our team understands the criticality of payer research and insights generation,
as well as their importance during drug development, pre-market launch
strategy, and post-marketing activities.
Schizophrenia
Overview
Schizophrenia, a persistent and
debilitating brain disorder, is typically characterized by two sets of
symptoms: positive and negative. Those with schizophrenia often experience
symptoms that leave them feeling fearful and withdrawn, with their speech and
behavior becoming so disorganized that they can be incomprehensible or alarming
to others. The ICD-10 outlines diagnostic criteria for seven subtypes of
schizophrenia, which include Paranoid, Catatonic, Postschizophrenic Depression,
Simple, Hebephrenic, Undifferentiated, and Residual schizophrenia.
Schizophrenic disorders are thought to have a complex origin involving genetic,
environmental, and neurotransmitter pathophysiological factors. Diagnosing
schizophrenia involves a psychiatric assessment since no definitive test exists
for the condition. In the United States, diagnosis relies primarily on the
Diagnostic and Statistical Manual (DSM-V), while in Europe, the International
Classification of Diseases (ICD), 10th revision, is often used. Schizophrenia
necessitates lifelong treatment, even when symptoms abate. Management includes
medication and psychosocial therapy, with occasional hospitalization. Treatment
is typically guided by a psychiatrist experienced in schizophrenia care.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by surveys* and interviews with payers (e.g.,
pharmacy directors / medical directors from managed care organizations with
Medicare and/or Commercial plans in the United States). If required, primary
market research with physicians is also done to understand the impact of
reimbursement environment on treatment decisions for current and emerging
brands.
*Survey and
interview discussion guide are customized based on client requirements
Deliverables
format:
- PowerPoint presentation
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Key business
questions answered:
- Market access and reimbursement for
current therapies
- Coverage on
plans
- Market access
restrictions
- Rebates and
contracting
- Factors
influencing formulary access
- HEOR
requirements and influence, etc.
- Expected market access and
reimbursement for key emerging therapies
- Level of
awareness
- Anticipated
coverage on plans
- Factors that
would improve market access
- Pricing, etc.
- Impact on brand use
- Key factors
driving and limiting brand use
- Best and worst
performers on market access, etc.
- Evolving environment
- Payer
expectations from emerging therapies
- New policies and
their expected impact, etc.
- Advise to drug
manufacturers and developers
Read more: Schizophrenia – Market Access and Reimbursement
Insights Report – 2025
Comments
Post a Comment